Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 1999, p. 3005-3007, Vol. 43, No. 12
Department of Pharmacy Practice, University
of Kansas Medical Center, Kansas City, Kansas
661601; Department of Pharmacy
Research,2 Office for Research
Administration,4 and Division of
Infectious Diseases,3 Hartford Hospital,
Hartford, Connecticut 06102; and Pfizer Central Research,
Groton, Connecticut 063405
Received 22 March 1999/Returned for modification 24 July
1999/Accepted 8 September 1999
Trovafloxacin pharmacokinetics were evaluated in 12 subjects with
AIDS. By using a randomized design, single 200-mg doses of oral
trovafloxacin and intravenous alatrofloxacin were administered. The
mean absolute bioavailability was 91%. The pharmacokinetics of
trovafloxacin when administered orally as the active form or intravenously as the prodrug (alatrofloxacin) are not altered in
subjects with AIDS compared to those in healthy adults.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Oral Bioavailability and Pharmacokinetics of
Trovafloxacin in Patients with AIDS
*
Corresponding author. Mailing address: Division of
Infectious Diseases, Hartford Hospital, Hartford, CT 06102. Phone:
(860) 545-3941. Fax: (860) 545-5112. E-mail:
dnicola{at}harthosp.org.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»